Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 8235 results

  1. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542

    In development Reference number: GID-TA11525 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  5. Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [TSID12303]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [TSID12299]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Xanomeline tartrate–trospium chloride for treating schizophrenia [TSID12311]

    Awaiting development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 June 2016

  11. Chronic anal fissure: botulinum toxin type A injection (ESUOM14)

    Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making

    Evidence summary
    Published
    25 June 2013

  12. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

    Evidence summary
    Published
    23 September 2014

  13. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

    Evidence summary
    Published
    1 March 2016

  14. Premature ejaculation: dapoxetine (ESNM40)

    Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

    Evidence summary
    Published
    14 May 2014

  15. Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)

    Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

    Evidence summary
    Published
    8 July 2014